Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Physics

Quantum Mechanics

Medicine

Pathology

Psychology

Show all topics

DOI

10.1016/s1473-3099(24)00376-1